shutterstock_2131359385_sruilk
9 November 2023BiotechnologyMarisa Woutersen

Taiwan company fails to overturn PTAB decision over eye treatment patent

Federal Circuit rejects appeal in patent dispute with California’s Cloudbreak Theraputics | Court stated failure to prove concrete injury.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
10 May 2019   Novartis is set to acquire assets associated with Xiidra ((lifitegrast ophthalmic solution), a dry eye treatment, from Takeda.
Americas
22 March 2018   Novartis has accused competitor Regeneron of patent infringement through the latter’s sale of Eylea and Zaltrap.